Carl Zeiss Meditec, the German ophthalmic and microsurgery equipment maker, has fallen roughly 78 percent over five years and about 26 percent this year alone. It has withdrawn guidance, replaced a chief executive who departed abruptly, and been downgraded by both Goldman Sachs and Bernstein.
The analyst community cannot agree on what that means, and the disagreement is instructive.
One discounted cash flow model puts fair value around €80.63 against a share price near €29.30, which reads as heavily undervalued. The most-followed analyst narrative puts fair value at about €30.19, roughly where it trades. Consensus target sits below the last close. Ratings range from strong buy with a €75 target to sell.
Same company, same accounts, same week. The spread is not a disagreement about arithmetic. It is a disagreement about whether the earnings base is real.
The operating picture explains why. First-quarter sales missed by two percent with organic growth at minus 2.1 against an expected plus 1.2. Adjusted EBIT came in at €10 million against a €25.6 million consensus, a sixty percent miss. Ophthalmic devices posted minus 2.4 percent organic growth with a negative EBIT margin. Order intake fell 9.7 percent, though against a strong prior year that had grown 21.4 percent. Margins fell 500 basis points year on year. The named causes are Chinese volume-based procurement, intraocular lens re-registration problems in China, foreign exchange, tariffs affecting manufacturing in Germany and Singapore, and an unfavourable product mix.
Set against that: gross margin of 52.8 percent, revenue over €2.2 billion, more than half of it recurring, a solid balance sheet, a dividend, and genuine market leadership in its niches.
Which is exactly the shape of the hardest decision in business, and every operator eventually faces the small version.
The cafe with a good room, a loyal lunchtime trade and an owner who wants out is available at a price that looks absurd. Two experienced people can look at the same set of accounts and reach opposite conclusions, because the question is not what it earned. It is whether the thing that broke is cyclical or structural. If the office block down the road emptied temporarily, the price is a gift. If that block is being converted to flats, the price is arithmetic and the arithmetic is correct.
The discount tells you nothing on its own. What tells you something is whether you can name the mechanism by which the lost earnings come back, and put a date on it.
For Carl Zeiss the mechanism is specific and checkable: does Chinese procurement pressure ease, does the lens re-registration clear, does the product mix normalise. Those are answerable questions with observable answers.
Five-year change minus 78 percent. Financial health scored five out of six.
Nobody is arguing about the balance sheet.
